MedTrace Logo

Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes

NCT01691079 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-06-05

Study results available
· View outcomes & findings →

Summary

This will be a double-blind placebo-controlled study in which we plan to study 40 competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests the athletes will randomly receive inhaled placebo or inhaled ipratropium bromide. We will compare the athletes' airway response to the exercise challenge with and without the active drug.

Conditions

  • Bronchospasm, Exercise-Induced

Interventions

DRUG

ipratropium bromide

Inhaled ipratropium bromide administered before exercise.

DRUG

Placebo

Inhaled placebo administered before exercise.

Sponsors & Collaborators

Principal Investigators

  • Mona Luke-Zeitoun · Assistant Clinical Professor (Volunteer)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01691079 on ClinicalTrials.gov